Evidence map›Paper›PMID 26481318›Full record

ArticleMolecular psychiatry2016

The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter.

I Gijselinck, S Van Mossevelde, J van der Zee, A Sieben, S Engelborghs, J De Bleecker, A Ivanoiu, O Deryck, D Edbauer, M Zhang and 12 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed, 2 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

147 citing papers in PubMed, 2 syntheses or guidelines pooled it, 246 citations in OpenAlex.

  1. Pooled it
  2. Blood DNA methylation as a potential biomarker of dementia: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018
    Pooled it
  3. Association between C9orf72 G4C2 repeat length and idiopathic Parkinson's disease in a Turkish cohort.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Wild-typemedRxiv : the preprint server for health sciences · 2026
    Article
  8. Review
  9. The spectrum ofFrontiers in neuroscience · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Targeting GeneInternational journal of molecular sciences · 2025
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. NAR molecular medicine · 2024
    Article
  19. Article
  20. Article

87 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 3 countries.

I GijselinckNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
S Van MosseveldeNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
J van der ZeeNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
A SiebenNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
S EngelborghsInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium.
J De BleeckerDepartment of Neurology, University Hospital Ghent and University of Ghent, Ghent, Belgium.
A IvanoiuDepartment of Neurology, Saint-Luc University Hospital and Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.
O DeryckDepartment of Neurology, General Hospital Sint-Jan Brugge-Oostende, Bruges, Belgium.
D EdbauerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
M ZhangTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
B HeemanNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
V BäumerNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
M Van den BroeckNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
M MattheijssensNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
K PeetersNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
E RogaevaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
P De JongheNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
P CrasInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium.
J-J MartinInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium.
P P de DeynInstitute Born-Bunge, University of Antwerp, Antwerp, Belgium.
M CrutsNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
C Van BroeckhovenNeurodegenerative Brain Diseases Group VIB Department of Molecular Genetics, Antwerp, Belgium.
University of Antwerp · BEVIB-UAntwerp Center for Molecular Neurology · BEAntwerp University Hospital · BEAZ Sint-Jan · BEGhent University Hospital · BELudwig-Maximilians-Universität München · DEOccupational Cancer Research Centre · CAUCLouvain · BEUniversity of Toronto · CAZNA Middelheim Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathological expansion of a G4C2 repeat, located in the 5' regulatory region of C9orf72, is the most common genetic cause of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). C9orf72 patients have highly variable onset ages suggesting the presence of modifying factors and/or anticipation. We studied 72 Belgian index patients with FTLD, FTLD-ALS or ALS and 61 relatives with a C9orf72 repeat expansion. We assessed the effect of G4C2 expansion size on onset age, the role of anticipation and the effect of repeat size on methylation and C9orf72 promoter activity. G4C2 expansion sizes varied in blood between 45 and over 2100 repeat units with short expansions (45-78 units) present in 5.6% of 72 index patients with an expansion. Short expansions co-segregated with disease in two families. The subject with a short expansion in blood but an indication of mosaicism in brain showed the same pathology as those with a long expansion. Further, we provided evidence for an association of G4C2 expansion size with onset age (P<0.05) most likely explained by an association of methylation state of the 5' flanking CpG island and expansion size in blood (P<0.0001) and brain (P<0.05). In several informative C9orf72 parent-child transmissions, we identified earlier onset ages, increasing expansion sizes and/or increasing methylation states (P=0.0034) of the 5' CpG island, reminiscent of disease anticipation. Also, intermediate repeats (7-24 units) showed a slightly higher methylation degree (P<0.0001) and a decrease of C9orf72 promoter activity (P<0.0001) compared with normal short repeats (2-6 units). Decrease of transcriptional activity was even more prominent in the presence of small deletions flanking G4C2 (P<0.0001). Here we showed that increased methylation of CpGs in the C9orf72 promoter may explain how an increasing G4C2 size lead to loss-of-function without excluding repeat length-dependent toxic gain-of-function. These data provide insights into disease mechanisms and have important implications for diagnostic counseling and potential therapeutic approaches.

Indexed as

AdultAge of OnsetAmyotrophic Lateral SclerosisBelgiumC9orf72 ProteinCpG IslandsDNA MethylationDown-RegulationEpigenesis, GeneticEpigenomicsFemaleFrontotemporal Lobar DegenerationGenetic Predisposition to DiseaseHumansMaleMiddle AgedC9orf72 ProteinC9orf72 protein, humanProteins

Identifiers

PMID26481318
PMCPMC4960451
OpenAlexW1837901569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.